Dosing Recommended 4-Week Dosing Schedule (28-Day Cycle) 1 *Kisqali is indicated in combination with an AI as initial endocrine-based therapy for the treatment of pre-/peri-menopausal or post-menopausal women with HR+/HER2- aBC. Kisqali is...
Patient Guides View and download the KISQALI (Ribociclib) Patient Guide for your patients who have been prescribed with KISQALI. Available in English, Chinese and Malay...
Homepage Efficacy Nearly doubled median PFS benefit supported by 7.9-month increase in OS vs. placebo. 1 Discover the first and only therapy specifically for HR+/HER2- aBC patients with a PIK3CA mutation 2 Safety Optimize your patient's treatment with a...